Skip to main content
Clinical Trials/NCT05299619
NCT05299619
Completed
Not Applicable

A Prospective Study Assessing the Impact of Tixel Treatment of Peri-orbital Wrinkles on Dry Eye Symptoms and Signs in Patients With Dry Eye

Dr Ludger Hanneken1 site in 1 country40 target enrollmentMarch 28, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peri-orbital Wrinkles
Sponsor
Dr Ludger Hanneken
Enrollment
40
Locations
1
Primary Endpoint
Safety, Device related AE frequency in the study
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. Meibomian Gland Dysfunction (MGD) refers to the condition where the glands are not secreting enough oil or when the oil they secrete is of poor quality.

Tixel is a fractional skin rejuvenation system, which relies on direct thermal energy delivery, free of any radiation type such as laser, RF, etc. The energy is transferred via a continuously sterile, thermal titanium element (the "Tip"), located on the applicator (the "Handpiece"). In this study, the principal investigator will undertake standard treatment of periorbital wrinkles with Tixel and observe the effect on dry eye disease symptoms and signs.

Detailed Description

Tixel® (Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation). The system consists of a handpiece connected to a console. The handpiece applies a therapeutic element, the "tip", fixated on the distal section. The tip is comprised of a gold-plated copper base and a thin-walled titanium alloy cover. While treating patients for wrinkles, it has been observed that in several cases, treatment had an effect on subjects who have been suffering from a pre-condition of dry eye disease. The effect was expressed mainly by increased tearing. In this study, the principal investigator will undertake standard treatment of periorbital wrinkles with Tixel and observe the effect on dry eye disease symptoms and signs.

Registry
clinicaltrials.gov
Start Date
March 28, 2019
End Date
March 28, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Dr Ludger Hanneken
Responsible Party
Sponsor Investigator
Principal Investigator

Dr Ludger Hanneken

Principle investigator

Vallmedic Vision & Aesthetic

Eligibility Criteria

Inclusion Criteria

  • Mild to Moderate Periorbital wrinkles
  • OSDI score of at least 23
  • Noninvasive Tear film break up time (NIKBUT) ≤ 10 seconds
  • Willing and able to provide written informed consent.
  • Willing to participate in all study activities and instructions.

Exclusion Criteria

  • Pregnancy and breastfeeding
  • Lesions in the periorbital area
  • Acute severe blepharitis
  • Acute conjunctivitis
  • Other concomitant anterior eye disease

Outcomes

Primary Outcomes

Safety, Device related AE frequency in the study

Time Frame: 8 months

Any safety related event during the study will be recorded and analysed

NIBUT in Seconds

Time Frame: 8 months

Non-Invasive Break Up Time

Secondary Outcomes

  • Efficacy assessment - OSDI-Ocular Surface Disease Index Questionnaire changes from baseline(8 months)
  • Osmolarity mOsml/L(8 months)
  • Staining; Total Ocular Staining Score(8 month)

Study Sites (1)

Loading locations...

Similar Trials